Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEZanne: ABBV-706 + atezolizumab vs standard therapy in untreated ES-SCLC
CTR20260407Phase 2Active
- Sponsor
- AbbVie Inc.
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of turmetabart adizutecan in small cell lung cancer (SCLC), sponsored by AbbVie Inc.. Started Aug 2026; status: active.
02
Drugs
turmetabart adizutecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20260407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260407.